Kyrgyzstan's Ministry of Economy and Commerce has issued a statement announcing that the country has secured an investment agreement to construct a pharmaceutical complex, media reports.
The "Industrial Park of Life Sciences" project is set to include a drug plant, a laboratory, a training center, and storage facilities. The complex will be focused on the production of vital drugs, such as insulin and other medicines that are presently not manufactured within the country.
The project will be overseen by Netherlands-based Biopharmax BV, which is committed to building the complex by 2028, with construction commencing in 2024. Moreover, the company has pledged to train and employ the local population and to supply necessary medical products until the plant is fully operational.
Founded on June 21, 1977, in Amsterdam, Netherlands, Biopharmax BV is a parent company of Biopharmax Group in Israel. Its primary activity involves developing and implementing construction projects. Biopharmax has been catering to global leaders in the pharmaceutical industry for the past four decades.
Comments (0)